Abstract: Disclosed herein are compounds useful for detecting oxidants in a living cell, in a multicellular organism, or in a cell-free sample. In particular, disclosed herein are bioluminescent reporter compounds, and more particularly, fluorinated peroxy-caged-luciferin (PCL) compounds, compositions comprising such compounds, methods of using such compounds and compositions, and processes for preparing such compounds. Also disclosed herein are kits and methods for detecting and measuring peroxynitrite, and optionally, additional oxidants in a living cell, in a multicellular organism, or in a cell-free sample.
Type:
Grant
Filed:
February 18, 2014
Date of Patent:
May 9, 2017
Assignee:
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Inventors:
Marcelo Bonini, Nathan A. Sieracki, Alexander V. Lyubimov
Abstract: A method for preparing a ruthenium carbene complex precursor includes reacting a ruthenium refinery salt with a hydrogen halide to form a ruthenium intermediate, and reacting the ruthenium intermediate with an L-type ligand to form the ruthenium carbene complex precursor. A method for preparing a ruthenium vinylcarbene complex includes converting a ruthenium carbene complex precursor into a ruthenium hydrido halide complex, and reacting the ruthenium hydrido halide complex with a propargyl halide to form the ruthenium vinylcarbene complex. A method for preparing a ruthenium carbene complex includes converting a ruthenium carbene complex precursor into a ruthenium carbene complex having a structure (PR1R2R3)2Cl2Ru?CH—R4, wherein R1, R2, R3, and R4 are alike or different, and wherein covalent bonds may optionally exist between two or more of R1, R2, and R3 and/or two of R1, R2, and R3 taken together may optionally form a ring with phosphorous.
Abstract: The present invention provides a base generator having the structure of formula (1): wherein R1, R2, R3, R4, R5, and Y{circle around (?)} are defined as in the specification. The base generator of the present invention can be used for imidization of a polyimide precursor, promoting crosslinking of epoxy monomers, or crosslinking of polyurethane or polyurea.
Abstract: A zinc complex characterized in exhibiting an octahedral structure and being configured from repeating units represented by general formula (I): wherein L represents a linker region, and R1 represents a C1-4 alkyl group, which can have a halogen atom.
Abstract: The present invention provides an organic compound to be used in an electrochromic device. The organic compound has excellent oxidation-reduction repeating characteristics and shows high transparency in the bleached state without showing light absorption in the visible light region. The organic compound has a structure represented by Formula [1] according to claim 1. In Formula [1], A1 and A2 represent substituents, and at least one of A1 and A2 is an alkyl group having 1 to 20 carbon atoms, an alkoxy group having 1 to 20 carbon atoms, or an optionally substituted aryl group. R1 represents a substituent, X represents an electrochromic portion, and n is an integer of 1 to 3.
Abstract: The invention provides in part, conjugate compounds. The invention also provides synthesis methods for making the compounds, and uses of the compounds.
Type:
Grant
Filed:
November 28, 2012
Date of Patent:
April 4, 2017
Assignee:
Simon Fraser University
Inventors:
Robert N. Young, Stephen Arns, Anne Moreau, Mohammed Monzur Morshed, Romelo Gibe
Abstract: Compositions, kits, and methods for treatment of cancers are generally provided. In some embodiments, the compositions, kits, and methods comprise a platinum (e.g., Pt(II) or Pt(IV)) compound associated with a ligand (e.g., a beta-diketonate ligand) comprising a targeting moiety. Methods of synthesizing platinum (e.g., Pt(II) or Pt(IV)) compounds associated with a ligand comprising a targeting moiety are also provided.
Type:
Grant
Filed:
April 4, 2014
Date of Patent:
March 14, 2017
Assignee:
Massachusetts Institute of Technology
Inventors:
Stephen J. Lippard, Justin J. Wilson, Robert John Radford, Maria R. Chan, Daniel Y. Zhang
Abstract: There is provided a compound having Formula I In the formula: R1 can be alkyl, aryl, alkylaryl, or deuterated analogs thereof; R2 can be alkyl or deuterated alkyl; R3 can be H, D, aryl, or deuterated aryl; and R4-R6 are the same or different and can be H, D, alkyl, or deuterated alkyl. In the formula, at least one of the following conditions is met: (i) R1 is a secondary alkyl, a tertiary alkyl, aryl, alkylaryl, or deuterated analog thereof; (ii) R3 is aryl or deuterated aryl; (iii) at least one of R3-R6 is D.
Type:
Grant
Filed:
April 2, 2013
Date of Patent:
March 14, 2017
Inventors:
Jerald Feldman, Stephan James McLain, Ying Wang
Abstract: Disclosed are methods for screening for the binding affinity of chemical entities to other bioactive molecules. The screened chemical entities may be utilized in pharmaceutical composition or therapeutic methods for treating disease or disorders associated with the bioactive molecules including NEDD4-1.
Type:
Grant
Filed:
May 26, 2015
Date of Patent:
March 7, 2017
Assignee:
Northwestern University
Inventors:
Alexander V. Statsyuk, Stefan G. Kathman
Abstract: Gold(III) complexes with mixed ligands as anticancer agents. The gold(III) cations are coordinated to bidentate ligands having diamino functional groups: a diaminocyclohexane ligand and a 1,3-propylenediamine ligand. The diaminocyclohexane ligand can exist in both cis- and trans- configurations, resulting in isomeric gold(III) complexes. Also described are pharmaceutical compositions incorporating the gold(III) complexes, methods of synthesis, methods of treating cancer and methods of inhibiting cancer cell proliferation and inducing cancer cell apoptosis.
Type:
Grant
Filed:
September 30, 2016
Date of Patent:
March 7, 2017
Assignee:
King Fahd University of Petroleum and Minerals
Inventors:
Said Al-Jaroudi, Muhammad Altaf, Abdulaziz Al-Saadi, Anvarhusein Abdulkadir Isab
Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
Type:
Grant
Filed:
April 26, 2016
Date of Patent:
February 28, 2017
Assignee:
Allergan, Inc.
Inventors:
Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
Abstract: Methods for preparing disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds that correspond to general formula (I) are described. Also described are pharmaceutical compositions that include the compounds, and methods of using the compounds and compositions for the treatment of chemokine-mediated diseases.
Abstract: Compounds of formula (I) wherein R1, R4, R8, X and Y as defined herein are provided as useful for the inhibition of certain types of cancer cells, amongst others, breast cancer cells, or for the manufacture of anti-cancer agents.
Abstract: Provided are a polycyclic pyrazolinone derivative indicated by general formula (1) (in the formula, R1, X1, X2, X3, and Y indicate the definitions provided in the Specification) and a herbicide comprising same as effective component thereof.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
February 28, 2017
Assignees:
Sagami Chemical Research Institute, Kaken Pharmaceutical Co., Ltd.
Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of using these chemical entities, e.g., for treatment of cancer are described.
Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.
Type:
Grant
Filed:
August 30, 2013
Date of Patent:
February 21, 2017
Assignee:
Tetraphase Pharmaceuticals, Inc.
Inventors:
Xiao-Yi Xiao, Roger B. Clark, Diana Katharine Hunt, Cuixiang Sun, Magnus P. Ronn, Wu-Yan Zhang, Minsheng He
Abstract: Monomeric gold(I) complexes as anticancer agents. The gold(I) complexes are coordinated to mixed ligands: one N-heterocyclic carbene ligand and one monodentate dithiocarbamate-based ligand. Pharmaceutical compositions incorporating the gold(I) complexes, methods of synthesis, methods of treating cancer and methods of inhibiting cancer cell proliferation and inducing cancer cell apoptosis are also provided.
Type:
Grant
Filed:
May 6, 2015
Date of Patent:
February 21, 2017
Assignee:
King Fahd University of Petroleum and Minerals
Inventors:
Muhammad Altaf, Anvarhusein Abdulkadir Isab
Abstract: Provided is a method for producing 5-hydroxy-1H-imidazole-4-carboxamide.3/4 hydrate, including: reacting 2-aminomalonamide with a compound represented by the following formula [1] in the presence of a carboxylic acid to obtain 5-hydroxy-1H-imidazole-4-carboxamide: wherein, in formula [1], each R independently represents a C1-3 alkyl group; reacting the resulting 5-hydroxy-1H-imidazole-4-carboxamide with an acidic compound to obtain a 5-hydroxy-1H-imidazole-4-carboxamide acid salt or a hydrate thereof; and reacting the resulting 5-hydroxy-1H-imidazole-4-carboxamide acid salt or hydrate thereof with a salt in the presence of an acidic solvent to obtain the 5-hydroxy-1H-imidazole-4-carboxamide.3/4 hydrate.
Abstract: The present invention comprises compounds and compositions thereof for enhanced drug delivery. Pro-drug and double pro-drug derivatives of corticosteroids non-steroid anti-inflammatory drugs (NSAIDs), and ruboxistaurin for delivery to the eye are provided. The compounds and compositions are useful for treating various ocular diseases, including ocular diseases effecting the posterior segments of the eye. In addition, the present invention is directed to particle in particle carrier formulations for sustained release of therapeutic agents.
Type:
Grant
Filed:
November 16, 2012
Date of Patent:
February 7, 2017
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY